Therapeutic strategies for COVID-19: progress and lessons learned
G Li, R Hilgenfeld, R Whitley, E De Clercq - Nature Reviews Drug …, 2023 - nature.com
Abstract The coronavirus disease 2019 (COVID-19) pandemic has stimulated tremendous
efforts to develop therapeutic strategies that target severe acute respiratory syndrome …
efforts to develop therapeutic strategies that target severe acute respiratory syndrome …
The SARS‐CoV‐2 main protease (Mpro): Structure, function, and emerging therapies for COVID‐19
Q Hu, Y Xiong, GH Zhu, YN Zhang, YW Zhang… - MedComm, 2022 - Wiley Online Library
The main proteases (Mpro), also termed 3‐chymotrypsin‐like proteases (3CLpro), are a
class of highly conserved cysteine hydrolases in β‐coronaviruses. Increasing evidence has …
class of highly conserved cysteine hydrolases in β‐coronaviruses. Increasing evidence has …
Structural basis for replicase polyprotein cleavage and substrate specificity of main protease from SARS-CoV-2
The main protease (M pro) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-
2) is a key enzyme, which extensively digests CoV replicase polyproteins essential for viral …
2) is a key enzyme, which extensively digests CoV replicase polyproteins essential for viral …
Targeting SARS-CoV-2 main protease for treatment of COVID-19: covalent inhibitors structure–activity relationship insights and evolution perspectives
The viral main protease is one of the most attractive targets among all key enzymes involved
in the SARS-CoV-2 life cycle. Covalent inhibition of the cysteine145 of SARS-CoV-2 MPRO …
in the SARS-CoV-2 life cycle. Covalent inhibition of the cysteine145 of SARS-CoV-2 MPRO …
Structure and function of SARS-CoV and SARS-CoV-2 main proteases and their inhibition: A comprehensive review
Severe acute respiratory syndrome-associated coronavirus (SARS-CoV) identified in 2003
infected∼ 8000 people in 26 countries with 800 deaths, which was soon contained and …
infected∼ 8000 people in 26 countries with 800 deaths, which was soon contained and …
SARS-CoV-2 antiviral therapy
The development of effective antiviral therapy for COVID-19 is critical for those awaiting
vaccination, as well as for those who do not respond robustly to vaccination. This review …
vaccination, as well as for those who do not respond robustly to vaccination. This review …
The research progress of SARS-CoV-2 main protease inhibitors from 2020 to 2022
X Pang, W Xu, Y Liu, H Li, L Chen - European Journal of Medicinal …, 2023 - Elsevier
The novel coronavirus disease 2019 (COVID-19) caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) has spread worldwide. The main protease (M pro) of …
syndrome coronavirus 2 (SARS-CoV-2) has spread worldwide. The main protease (M pro) of …
Development of optimized drug-like small molecule inhibitors of the SARS-CoV-2 3CL protease for treatment of COVID-19
Abstract The SARS-CoV-2 3CL protease is a critical drug target for small molecule COVID-
19 therapy, given its likely druggability and essentiality in the viral maturation and replication …
19 therapy, given its likely druggability and essentiality in the viral maturation and replication …
Perspectives on SARS-CoV-2 main protease inhibitors
The main protease (Mpro) plays a crucial role in severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) replication and is highly conserved, rendering it one of the …
coronavirus 2 (SARS-CoV-2) replication and is highly conserved, rendering it one of the …
Recent advances in SARS-CoV-2 main protease inhibitors: from nirmatrelvir to future perspectives
A Citarella, A Dimasi, D Moi, D Passarella, A Scala… - Biomolecules, 2023 - mdpi.com
The main protease (Mpro) plays a pivotal role in the replication of severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) and is considered a highly conserved viral target …
syndrome coronavirus 2 (SARS-CoV-2) and is considered a highly conserved viral target …